Correction to Lancet Oncol 2015; 16: 1473–82 (The Lancet Oncology (2015) 16(15) (1473–1482), (S1470204515002909) (10.1016/S1470-2045(15)00290-9));Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages 1473-1482

  Motzer, Robert J ^a   Hutson, Thomas E ^b   Glen, Hilary ^c   Michaelson, M Dror ^d   Molina, Ana ^e   Eisen, Timothy ^f   Jassem, Jacek ^g   Zolnierek, Jakub ^h   Maroto, Jose Pablo ⁱ   Mellado, Begoña ^j   Melichar, Bohuslav ^k   Tomasek, Jiri ^l   Kremer, Alton ^m   Kim, Han Joo ^m   Wood, Karen ⁿ   Dutcus, Corina ^m   Larkin, James ^o  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ Novartis   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k PALACKÝ UNIVERSITY   (Czech Republic)

^l MASARYK UNIVERSITY   (Czech Republic)

^m EISAI INC   (United States)

ⁿ EISAI CO LTD   (Japan)

^o INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; LENVATINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; CONSTIPATION; CONTROLLED STUDY; COUGHING; CZECH REPUBLIC; DECREASED APPETITE; DIARRHEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INSOMNIA; KIDNEY METASTASIS; LETHARGY; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH PAIN; MOUTH ULCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL CHEST PAIN; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POLAND; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SPAIN; STOMATITIS; TOOTH PAIN; UNITED KINGDOM; UNITED STATES; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOLUME OF DISTRIBUTION; VOMITING; XEROSTOMIA; CARCINOMA, RENAL CELL; CLINICAL TRIAL; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; SECONDARY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; EVEROLIMUS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; QUINOLINES;

EID: 84955253186     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30672-7     Document Type: Erratum

References (24)

1. Clinical practice guidelines in oncology, version 3: kidney cancer 2015, NCCN, National Comprehensive Cancer Network, Fort Washington.
2. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015, 67:913-924.
3. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008, 14:5459-5465.
4. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008, 122:664-671.
5. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013, 340:97-103.
6. Molina AM, Hutson TE, Larkin J, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol 2014, 73:181-189.
7. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
8. Clopper CJ, Pearson ES The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.
9. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015, 372:621-630.
10. Lenvima (lenvatinib) prescribing information 2015, Eisai, Eisai Inc, WoodcliffLake.
11. Afinitor (everolimus) prescribing information 2015, Novartis Pharmaceuticals, Novartis Pharmaceuticals Corporation, East Hanover.
12. Eskens FA, Verweij J The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer 2006, 42:3127-3139.
13. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013, 14:552-562.
14. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15:286-296.
15. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(suppl 3):iii49-iii56.
16. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014, 32:760-767.
17. Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011, 12:673-680.
18. Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014, 32:752-759.
19. McDermott DF, Manola J, Pins M, et al. The BEST trial (E2804): a randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2013, 31(suppl 6). abstract 345.
20. Ravaud A, Barrios CH, Alekseev B, et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alpha-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2015, 26:1378-1384.
21. Harshman LC, Barbeau S, McMillian A, Srinivas S A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clin Genitourin Cancer 2013, 11:100-106.
22. Stjepanovic N, Capdevila J Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics 2014, 8:129-139.
23. Sonpavde G, Willey CD, Sudarshan S Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig Drugs 2014, 23:305-315.
24. Chen ZY, Shi M, Peng LX, et al. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. J Transl Med 2012, 10:245.